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Interferon (IFN) in combination with ribavirin is the main treatment for hepatitis C virus (HCV) infection. The sensitivity or
resistance of the virus to IFN has been linked to certain types of the interferon sensitivity determining region (ISDR) and
PKR-eIF2 phosphorylation homology domain (PePHD) sequences in the NS5A and E2 regions of the viral genome,
respectively. In search of the other potential mechanisms of HCV resistance to IFN, we tested the effect of IFN- on
translational activity of the HCV IRES in various cell types. Using bicistronic dual luciferase reporter RNAs in direct RNA
transfection studies, we found that the cap-dependent translation was dramatically inhibited by IFN (5- to 16-fold), whereas
HCV IRES translation was inhibited only marginally in two hepatoma cell lines, Huh7 and HepG2 cells. No difference in IFN
sensitivity was observed among IRESs of genotypes 1a, 1b, and 2a. Translation under the control of encephalomyocarditis
virus (EMCV) IRES was inhibited by IFN to the same extent as cap-dependent translation. In cells of nonhepatic origin (HeLa
and Raji), however, HCV IRES-, EMCV IRES-, and cap-dependent translation were dramatically inhibited to similar levels. The
PKR expression level was enhanced by IFN in all cells, but eIF2 phosphorylation level was not changed, probably due to
the absence of double-stranded RNA species. There was also no evidence of RNase L activation. Therefore, inhibition of
translation by IFN under these conditions was probably mediated by novel IFN-induced inhibitory pathways, independent of
eIF2 phosphorylation, while HCV IRES was not subject to this inhibition in hepatoma cell lines. Thus, HCV IRES-driven
translation was resistant to IFN-induced, eIF2-independent inhibition in human hepatoma cells that are frequently used inal mechINTRODUCTION
Hepatitis C virus (HCV) is one of the major causes of
chronic hepatitis, liver cirrhosis, and hepatocellular car-
cinoma. Approximately 175 million people are infected
with HCV worldwide (Sarbah and Younossi, 2000). The
most widely used treatment includes a combination ther-
apy with ribavirin and interferon-alpha (IFN-); however,
a large percentage of patients do not respond to the
therapy. The antiviral effect of type 1 interferons results
from engagement of at least three major cellular defense
systems (reviewed by Stark et al., 1998). First, double-
stranded RNA (dsRNA)-activated protein kinase, PKR,
phosphorylates the -subunit of the translation initiation
factor eIF2, resulting in general inhibition of protein syn-
thesis. Second, the 2-5-oligoadenylate synthetase-ribo-
nuclease L (2-5-OAS-RNase L) system degrades viral
RNA, and third, the Mx proteins inhibit viral RNA synthe-
sis. Other, yet uncharacterized, IFN-regulated antiviral
pathways are certain to exist in mammals (Zhou et al.,
1999; Diamond and Harris, 2001). Many viruses have
evolved mechanisms for evading some of the antiviral195effects of IFN (Stark et al., 1998). These include virus-
associated RNAs that bind but do not activate PKR, such
as those of adenovirus and Epstein–Barr virus (Anderson
and Fennie, 1987; Clarke et al., 1991), as well as viral
proteins that inhibit PKR both indirectly and directly,
which include vaccinia virus E3L (Beattie et al., 1995),
sigma 3 capsid protein of reovirus (Imani and Jacobs,
1988), and TAT of HIV (Roy et al., 1990).
HCV, too, is believed to have evolved at least two
mechanisms for suppression of the IFN-induced antiviral
state. The NS5A protein contains a sequence termed
interferon sensitivity determining region (ISDR) that was
linked to HCV genotype 1b resistance to IFN therapy
(Enomoto et al., 1996). Gale and colleagues (Gale et al.,
1997, 1998) showed that NS5A derived from IFN-resistant
HCV type 1 binds to PKR and inhibits its activity. Previous
studies in our laboratory have identified another poten-
tial mechanism of PKR inhibition by IFN-resistant HCV
genotypes (Taylor et al., 1999); namely, the viral envelope
protein E2 from the IFN-resistant genotypes 1a and 1b
contains a PKR-eIF2-phosphorylation homology do-
main (PePHD), which enables it to bind PKR and inhibit
its kinase activity. Both proposed mechanisms will inhibitstudies on HCV replication. This may present a new potenti
steps of virus infection. © 2002 Elsevier Science (USA)
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studies questioned the PKR-dependent manner of NS5A-
mediated suppression of the antiviral state (Francois et
al., 2000; Podevin et al., 2001). Furthermore, the PePHD
sequence is highly conserved, thus unlikely to explain
the variation of IFN sensitivity within each genotype.
Therefore, it is likely that other mechanisms exist that
allow HCV to escape the effects of IFN.
Translation of HCV genomic RNA is initiated by inter-
nal ribosome entry (Tsukiyama-Kohara et al., 1992; Wang
et al., 1993). The internal ribosome entry site (IRES) of
HCV is unique in its ability to recruit the 40S-ribosomal
subunit without the help of the canonical translation
initiation factors eIF4A, eIF4B, and eIF4F (Pestova et al.,
1998). The higher-order RNA structure of the HCV IRES
positions the preinitiation complex precisely at the initi-
ating AUG codon (Kieft et al., 2001; Spahn et al., 2001).
Despite its limited requirements for translation initiation
factors, HCV IRES-driven translation cannot initiate with-
out eIF2 (Pestova et al., 1998). Because the -subunit of
eIF2 is a substrate of the IFN-induced protein kinase
PKR, HCV IRES translation is expected to be inhibited by
IFN. PKR requires dsRNA for activation and will not
phosphorylate eIF2 in the absence of virus replication.
In this study we observed inhibition of reporter mRNA
translation by IFN even in the absence of viral infection,
suggesting the existence of alternative IFN-induced in-
hibitory pathways independent of dsRNA. Interestingly, in
cells of hepatic origin, HCV IRES-driven translation was
not significantly inhibited by IFN, while cap- and EMCV
IRES-dependent translation was reduced. This observa-
tion may provide another mechanism for HCV to escape
the effects of IFN.
RESULTS
Reporter constructs
To study the effects of IFN on HCV IRES-driven trans-
lation in comparison with cap-dependent translation, we
developed bicistronic reporter constructs with Renilla
and firefly luciferase reporter genes (Fig. 1). The Renilla
luciferase gene is expressed by a cap-dependent mech-
anism, and firefly luciferase is controlled by HCV or
EMCV IRES. We tested IRES elements derived from HCV
genotypes 1a, 1b, and 2a (HCV-B-1a, HCV-B-1b, and
HCV-B-2a, respectively). A monocistronic firefly lucif-
erase reporter construct (HCV-M-1b) containing HCV
IRES (genotype 1b) was also made for comparison. We
chose to use a direct RNA transfection method to avoid
any possible complication from DNA-dependent tran-
scription in the DNA transfection method or the artificial
effects of the vaccinia virus infection method, so that the
effect of IFN on translation could be measured directly.
All reporter constructs contained a T7 RNA polymerase
promoter upstream of the Renilla luciferase gene for in
vitro transcription. The constructs were first tested in
vitro in rabbit reticulocyte lysates; all of them produced
Renilla and firefly luciferase proteins of expected sizes
(Fig. 1).
HCV IRES-driven translation is insensitive to IFN- in
hepatocyte cell lines
To study the effect of IFN- on HCV translation, we first
investigated the response of HCV IRES-driven translation
to various concentrations of IFN- in Huh7 cells, a hep-
atoma-derived cell line. Capped in vitro RNA transcripts
of the HCV-B-1b bicistronic reporter construct were
transfected into Huh7 cells pretreated with IFN- for
16 h, and cell lysates were analyzed by dual luciferase
reporter assay 8 h posttransfection. The levels of cap-
dependent translation, as measured by Renilla luciferase
activity, decreased with the increasing concentrations of
IFN. At 1000 u/ml IFN, it was approximately 10% of that in
untreated cells (Fig. 2). Surprisingly, HCV IRES-driven
translation measured by firefly luciferase activity did not
change significantly with the increasing concentration of
IFN. Even at IFN concentration as high as 5000 u/ml, the
HCV IRES activity remained unaffected.
To test whether the insensitivity of HCV IRES to IFN
inhibition is cell-specific, we examined the effect of IFN
treatment on translation in several different cell types.
Along with the HCV-B-1b bicistronic reporter construct,
we tested the construct containing EMCV IRES to deter-
mine whether other IRES elements are similarly insensi-
tive to IFN treatment. Transcripts of the bicistronic con-
FIG. 1. (A) Diagram of the mono- and bicistronic reporter constructs
used in this study. Boxes indicate the Renilla and the firefly luciferase
reporter genes. Clear box 5 to the firefly luciferase gene indicates part
of the HCV core-coding region fused to the luciferase. (B) Translation of
the reporter constructs in vitro. The left three lanes show translation
products of bicistronic constructs containing IRESs of HCV genotypes
1a, 1b, and 2a (HCV-B-1a, HCV-B-1b, and HCV-B-2a). The right two
lanes show translation products of the bicistronic construct with EMCV
IRES (EMCV-RF) and the monocistronic HCV reporter (HCV-M-1b),
respectively. RNA transcripts were translated in rabbit reticulocyte
lysates with 35S-methionine. Translation products were analyzed by
electrophoresis in 10% polyacrylamide gel.
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structs were transfected into Huh7, HepG2, HeLa, and
Raji cells. All experiments were done at an IFN concen-
tration of 1000 u/ml. At this concentration, HCV IRES-
mediated translation was only slightly inhibited in Huh7
cells. In contrast, both cap- and EMCV IRES-dependent
translations were reduced to less than 10% of untreated
cells (Fig. 3, Table 1). Similar results were observed in
another hepatoma cell line HepG2, although the overall
inhibition of the EMCV IRES- and cap-dependent trans-
lation was not as pronounced as in Huh7 cells. Surpris-
ingly, in HeLa and Raji cells, HCV IRES-dependent trans-
lation was inhibited by IFN to almost the same extent as
cap-dependent and EMCV IRES-driven translation (Fig. 3,
Table 1). These results suggest that the insensitivity of
HCV IRES to IFN is specific for hepatic cells and that it is
specific for HCV but not EMCV IRES.
Since HCV IRES is located at the 5 end of the viral
RNA, but not internally as in the bicistronic reporter
RNAs, we tested if HCV IRES is insensitive to IFN when
located at the 5 end of the reporter RNA. For this pur-
pose, we examined HCV IRES activity in the context of a
monocistronic reporter construct (Fig. 1). Uncapped RNA
transcripts of the monocistronic constructs HCV-M-1b
and GL-EMCV (Ito et al., 1998) were transfected into
Huh7 cells. The results showed that in IFN-treated Huh7
cells, HCV IRES translation was only slightly inhibited
FIG. 2. Effect of increasing concentrations of IFN- on translation.
Huh7 cells pretreated with various concentrations of IFN- for 16 h
were transfected with capped RNA transcripts of HCV-B-1b bicistronic
dual luciferase reporter constructs. Cells were harvested 8 h after
transfection and lysates were analyzed by dual luciferase reporter
assay. Cap-dependent translation (Cap, upper graph) is measured as
Renilla luciferase activity, and HCV IRES-driven translation (HCV IRES,
lower graph) is measured as firefly luciferase activity.
FIG. 3. Effects of IFN- on translation in different cell types. HCV and EMCV IRES-driven translation is represented as firefly luciferase activity, and
cap-dependent translation is represented by Renilla luciferase activity. Solid bars show translation in the untreated control cells and hatched bars
show translation in cells treated with 1000 u/ml IFN-.
TABLE 1
Fold Inhibition of Translation by IFN- in Different Cell Types
HCV IRES EMCV IRES Cap
Huh7 1.5 11.0 16.6
HepG2 1.7 3.2 4.4
HeLa 4.1 4.8 8.7
Raji 5.0 7.5 10.5
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(twofold), whereas EMCV IRES activity was reduced
more dramatically (eightfold; Fig. 4). These results indi-
cate that the difference in IFN sensitivity between the
HCV and the EMCV IRES in Huh7 cells was the intrinsic
property of the IRES, but did not depend on their posi-
tions on the RNA.
IRES elements of different HCV genotypes are
equally insensitive to IFN in Huh7 cells
Patients infected with HCV genotype 1 have been
shown to be the least responsive to IFN therapy. This
was partially attributed to the specific sequences in the
NS5A and E2 proteins, which can interact with PKR and
inhibit its activity. However, these potential mechanisms
could not explain all the clinical IFN sensitivity or resis-
tance among HCV patients. To determine whether IRESs
of various genotypes have different sensitivity to inhibi-
tion by IFN, we tested bicistronic constructs containing
IRESs derived from genotypes 1a, 1b, and 2a in Huh7
cells. Translation driven by these IRESs was equally
insensitive to IFN inhibition (Fig. 5), suggesting that the
differential sensitivity of the different HCV genotypes to
IFN therapy is not due to the possible variation of the
IRES sensitivity to IFN.
Mechanism of HCV IRES insensitivity to IFN in Huh7
cells
The differential sensitivity of HCV IRES to IFN in hep-
atoma and nonhepatic cell lines suggested that the IFN
signaling pathways are different between these cells.
Previous studies on IFN response in the hepatic cell
types have shown that they are defective in some as-
pects of IFN signaling (Keskinen et al., 1999). Further-
more, the difference in IFN sensitivity between the EMCV
and HCV IRES in hepatoma cell lines is consistent with
the previous findings that these two IRES elements are
translated by different mechanisms (Pestova et al., 1998)
and suggests that IFN targets these differences. We,
therefore, initiated examination of the IFN response path-
ways in these two cell lines. We first examined whether
the protein kinase PKR is upregulated in Huh7 cells in
response to IFN treatment. Western immunoblot analysis
of the cells treated with IFN showed a significant in-
crease in the total amount of PKR in both Huh7 and HeLa
cells treated with IFN (Fig. 6A), indicating that the IFN
signaling pathway was intact in both cell types. Since
PKR exerts its inhibitory effect on translation through
phosphorylation of eIF2, we also tested the effect of IFN
on the level of phosphorylated eIF2. Surprisingly, the
level of the phosphorylated eIF2 in both Huh7 and HeLa
cells was not increased following IFN treatment (Fig. 6B).
These results suggested that the induced PKR was not
activated. The failure of PKR activation is best explained
by the absence of dsRNA in this RNA transfection sys-
tem. This result was confirmed by immunoprecipitation
of eIF2 from 32P-orthophosphate-labeled cells (data not
shown). These combined results suggest that the inhibi-
tion of the cap- and EMCV IRES-dependent translation by
FIG. 4. Effects of IFN on translation of monocistronic reporter con-
structs. HCV and EMCV IRES-driven translation was measured as
firefly luciferase activity in Huh7 cells transfected with RNA transcripts
of the monocistronic constructs pHCV-M-1b and pGL-EMCV. Cells
were treated as described in Fig. 3.
FIG. 5. Comparison of IRES elements of different HCV genotypes in
Huh7 cells in the presence of IFN. Huh7 cells pretreated with IFN
were transfected with transcripts of bicistronic reporter constructs
containing IRES elements of different HCV genotypes, 1a, 1b, and 2a
(HCV-B-1a, HCV-B-1b, and HCV-B-2a). Cell lysates were analyzed by
dual luciferase reporter assay.
FIG. 6. Analysis of IFN-induced pathways in Huh7 and HeLa cells. (A)
PKR was detected by Western blot analysis in Huh7 and HeLa cell
lysates using a rabbit polyclonal antibody (M-515, Santa Cruz). (B)
eIF2 phosphorylation level was determined using an eIF2 (pS51)
phosphospecific rabbit polyclonal antibody (Biosource). (C) Northern
blot analysis of HCV-B-1b reporter RNA in Huh7 and HeLa cells treated
with IFN. (D) Primer extension analysis of p56 mRNA (RNA 561) in Huh7
and HeLa cells. (E) Detection of the IFN-induced p56 protein in Huh7
and HeLa cell lysates by Western immunoblot analysis using a rabbit
polyclonal antibody kindly provided by Dr. Ganes Sen.
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IFN in this system was mediated by a PKR-eIF2-inde-
pendent mechanism.
To test if increased RNA degradation may have been a
cause of translation inhibition in IFN-treated cells, we
analyzed total RNA from the cells transfected with the
reporter RNA (HCV-B-1b) by Northern blot analysis. In
both Huh7 and HeLa cells, bicistronic reporter construct
RNA levels were unchanged upon IFN treatment (Fig.
6C). This was not unexpected since, similar to PKR, the
IFN-induced 2-5 OAS/RNase L system responsible for
RNA degradation requires dsRNA for activation.
Another recently discovered IFN-induced translation
inhibitory pathway involves induction of the protein p56,
which binds eIF3 and inhibits translation initiation (Guo
et al., 2000). We analyzed total RNA from Huh7 and HeLa
cells for the presence of the p56 mRNA (mRNA 561)
using primer extension analysis. We also tested cell
lysates for the accumulation of the p56 protein. Both cell
types expressed similar levels of p56 mRNA and the
protein in response to IFN treatment, while neither p56
mRNA nor p56 protein was detected in untreated cells
(Figs. 6D and 6E), indicating that p56 expression was
induced to the same extent by IFN in both cell types. This
result further confirms that most of the IFN signaling
pathways were intact in hepatoma cells. However, HCV
IRES may respond to the IFN-induced genes differently
from the EMCV IRES in hepatoma cell lines.
DISCUSSION
In this study we demonstrated that, in the absence of
viral RNA replication, HCV IRES translation is almost
unaffected by IFN treatment in human hepatoma cells,
whereas cap-dependent and EMCV IRES-driven transla-
tion levels are significantly reduced. This unexpected
finding suggests that cell lines derived from human liver
differ from other cell types in some aspects of their
IFN-induced pathways. The relatively weak ability of he-
patic cells to fight viral infection has been addressed
previously (Keskinen et al., 1999). A study on Huh7 and
HepG2 cells demonstrated that these cells are unable to
produce type 1 IFNs in response to RNA virus replication
(Keskinen et al., 1999). Nevertheless, when treated with
exogenous IFN, these cells are capable of activating the
main elements of the IFN-induced pathways, although
they require a higher concentration of IFN than that
sufficient for other cell types (Melen et al., 2000). In this
study, we examined the direct effect of IFN treatment on
translation by using RNA transfection approach. This
approach enables exclusive study of the effects of IFN on
translation without other potential complicating factors
such as the effects on RNA transcription or vaccinia virus
infection, which are associated with other experimental
approaches. Furthermore, this approach is not compro-
mised by the modulating effects of viral proteins. Even in
the absence of viral replication, which will result in pro-
duction of dsRNA intermediates capable of activating
PKR and 2-5 OAS/RNase L, we observed significant
inhibition of translation in IFN-treated cells most likely by
a PKR-eIF2-independent mechanism. Interestingly, we
found that HCV IRES translation was highly resistant to
IFN in hepatoma cell lines, whereas EMCV IRES and
cap-dependent translation was very sensitive. These
findings provide an additional mechanism by which HCV
resists IFN effects. Furthermore, these findings raised an
interesting question regarding the validity of using the
subgenomic replicons for studying the effects of IFN on
HCV replication. These replicons typically contain EMCV
IRES to drive the expression of HCV proteins (Lohmann
et al., 1999; Guo et al., 2001). The reported sensitivity of
these systems to IFN (Blight et al., 2000; Guo et al., 2001)
could have reflected the sensitivity of EMCV IRES rather
than the true sensitivity of HCV replication.
Our results clearly show that the major mediator of the
IFN-induced translational inhibition, PKR, was upregu-
lated in both hepatic (Huh7) and nonhepatic (HeLa) cells.
However, phosphorylation levels of eIF2 were not al-
tered in either cell type after IFN treatment. This result
suggests that PKR is not activated in the absence of
dsRNA replication intermediates, although it is overpro-
duced in response to IFN treatment. Furthermore, IFN-
induced degradation of the reporter RNA mediated by
RNase L was not observed. Nevertheless, protein syn-
thesis was clearly affected, suggesting the existence of
alternative pathways for IFN-induced translation inhibi-
tion. Besides PKR-mediated phosphorylation of eIF2
and mRNA degradation by RNase L, an IFN-induced
protein p56 has recently been discovered that binds the
p48 subunit of the translation initiation factor eIF3 and
inhibits initiation of translation (Guo et al., 2000). In the
case of HCV IRES, eIF3 is required not for 40S-ribosomal
subunit binding, but for the 60S-subunit joining (Pestova
et al., 1998). Our primer extension analysis showed that
IFN induced expression of the p56 mRNA in both Huh7
and HeLa cells. By binding to eIF3, p56 would be ex-
pected to inhibit translation in general. However, our
data show that HCV IRES translation was not inhibited in
hepatoma cells, although p56 expression was induced
by IFN treatment. Thus, p56 may not be sufficient to
inhibit HCV IRES-driven translation. It is likely that an
accessory factor required for IFN action is defective in
Huh7 and HepG2 cells.
It is also conceivable that an as yet unidentified IFN-
induced translation inhibition pathway may be involved.
Existence of novel innate immune pathways has been
suggested by studies in mouse cells deficient in PKR and
RNase L that were able to resist infection by EMCV and
vesicular stomatitis virus (Zhou et al., 1999) and inhibit
translation of Dengue virus (Diamond and Harris, 2001)
after IFN treatment. IFN-induced inactivation of transla-
tion factors other than eIF2, such as eIF4G, is a poten-
tial possibility. eIF4G is required for both cap- and EMCV
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IRES-driven translation, but not for HCV IRES-driven
translation (Pestova et al., 1998).
Our observation that IRESs of different HCV genotypes
are equally insensitive to IFN inhibition in Huh7 cells is
not surprising. Other groups have demonstrated the lack
of correlation between any specific sequence within the
IRES and the susceptibility of HCV to IFN treatment
(Yamamoto et al., 1997). Clearly, the mechanism behind
the variation in IFN sensitivity among different viral ge-
notypes is more complex and cannot be explained by
differential sensitivity of viral IRESs to IFN-induced trans-
lational inhibition. Previous studies have implicated two
viral proteins, E2 and NS5A, in the differential suscepti-
bility of various HCV genotypes to IFN therapy (Gale et
al., 1997, 1998; Taylor et al., 1999). The inherent resis-
tance of HCV IRES to IFN is a feature likely shared by all
viral genotypes. This resistance may give the virus an
important advantage at the early stages of infection be-
fore any viral RNA replication has occurred. This would
allow HCV to complete the first stages of its life cycle
(translation of viral proteins) without interference from
the host defense systems. When viral RNA replication
begins and dsRNA species are generated, the PKR-
induced antiviral state in IFN-treated cells will inhibit
further virus protein translation, unless PKR is inactivated
by viral proteins such as E2 and/or NS5A. Finally, it
remains to be tested whether the hepatoma cell lines
Huh7 and HepG2, which are frequently used in studies
on HCV translation and replication, are representative of
human liver cells in various aspects of their biology,
including IFN-induced defense pathways.
MATERIALS AND METHODS
Reporter constructs
For monocistronic firefly luciferase reporter con-
structs, the HCV IRES sequence, including part of the
core protein-coding region, of genotype 1b (nt 1–392)
was amplified by PCR from the full-length clone pHCV-N
(Beard et al., 1999) with the addition of flanking restriction
sites MluI and HindIII. The IRES sequence was cloned
into the MluI and HindIII sites of pGL3-basic plasmid
(Promega) upstream of the firefly luciferase reporter
gene to yield pHCV-M-1b. To make the bicistronic dual
luciferase reporter constructs, the Renilla luciferase cod-
ing region was PCR-amplified from the pRL-SV40 vector
(Promega) and cloned into the KpnI and MluI sites of
pGL3-basic. The resulting plasmid, pRL-GL, was di-
gested with MluI and HindIII, and PCR-amplified EMCV
IRES and HCV IRES sequences (nt 1–392) of genotypes
1a, 1b, and 2a were inserted to create pEMCV-RF, pHCV-
B-1a, -1b, and -2a. IRES sequences of HCV genotypes 1a,
1b, and 2a were derived from the full-length HCV clones
pCV-H77C (Yanagi et al., 1997), pHCV-N (Beard et al.,
1999), and pJ6CF (Yanagi et al., 1999), respectively. Prior
to in vitro transcription, the constructs were digested
with restriction endonuclease EagI (bicistronic) or XbaI
(monocistronic), extracted with phenol-chloroform, and
precipitated with ethanol. The bicistronic constructs
were transcribed in vitro using T7 RNA polymerase sys-
tem, mMessage mMachine (Ambion), to produce capped
transcripts. The monocistronic constructs were tran-
scribed using T7 MegaScript (Ambion).
Cell lines, transfections, and reporter assays
Four human cell lines were used in this study: hepa-
toma cells Huh7 and HepG2, cervical carcinoma cells
HeLa, and B cell lymphoma Raji cells. Huh7 and HepG2
cell lines were maintained in DMEM media supple-
mented with 10% FBS, glutamine, nonessential amino
acids, penicillin, and streptomycin. HeLa cells were
maintained in the same media without the nonessential
amino acids. Raji cells were grown in suspension in the
RPMI 1640 media supplemented with 20% FBS, glu-
tamine, penicillin, and streptomycin. Cells were pre-
treated with recombinant human IFN, 1000 u/ml
(Fitzgerald) for 16 h. Huh7, HepG2, and HeLa cells were
transfected with RNA transcripts using DMRIE-C reagent
(Gibco-BRL), following the manufacturer’s instructions.
Raji cells were transfected by electroporation. Prior to
transfection, Raji cells were washed in serum-free RPMI
1640 medium, and then 107 cells were mixed with 50 g
of RNA in 0.5 ml of serum-free media in a 0.4-cm Gene
Pulser electroporation cuvette (Bio-Rad), incubated at
room temperature for 5 min, and electroporated at 300 V,
975 F, using a Gene Pulser II electroporator (Bio-Rad).
Cells were then incubated on ice for 15 min and trans-
ferred to flasks with the growth medium. Cells were
harvested 8 h after transfection. Cell lysates were ana-
lyzed by luciferase assay (monocistronic constructs) or
dual luciferase assay (bicistronic constructs) according
to the manufacturer’s instructions (Promega) using a
Lumat luminometer.
Immunoblot analysis
Cells were lysed in Triton lysis buffer (50 mM Tris–HCl,
pH 7.6, 150 mM NaCl, 0.5% Triton-X), 400 l per 6-cm
plate. Cell lysates were mixed with the 5 loading buffer
(0.225 M Tris–HCl, pH 6.8, 50% glycerol, 5% SDS, 0.05%
bromphenol blue, 0.25 M DTT), and 15 l of each sample
was resolved by 10% SDS–PAGE. Proteins were trans-
ferred to a Hybond-C nitrocellulose membrane (Amer-
sham) by semidry transfer and blocked in 5% skim milk
solution in PBS-T (0.1% Tween) at 4°C overnight. Anti-PKR
rabbit polyclonal antibody (M-515, Santa Cruz) was used
at 1:200 dilution. Anti-eIF2 (pS51) phosphospecific rabbit
polyclonal antibody (Biosource) was used at 1:500 dilu-
tion. Anti-p56 rabbit polyclonal antibody (generous gift of
Dr. Ganes Sen, the Cleveland Clinic Foundation) was
diluted 1:1000. HRP-conjugated donkey anti-rabbit sec-
ondary antibody (Santa Cruz) was used at 1:1000 dilution.
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Detection was performed using ECL-plus system (Amer-
sham Pharmacia Biotech).
RNA extraction and analysis
Total RNA from cultured cells was extracted by using
the RNeasy RNA isolation kit (Qiagen). For Northern blot
analysis, total RNA (5 g) was resolved on a 1% agarose
formaldehyde denaturing gel, transferred to a Gene-
Screen nylon membrane, and hybridized with the 32P-
labeled riboprobe complementary to the firefly luciferase
coding sequence, essentially as previously described
(Seeley et al., 1992; Koev et al., 1999). Primer extension
was performed on total RNA isolated from mammalian
cells as described previously (Zhai et al., 1997). Essen-
tially, 32P 5-end-labeled DNA oligonucleotide primer
complementary to nt 59–80 of the p56 mRNA (interferon-
induced protein with tetratricopeptide repeats 1, Gen-
Bank Accession No. NM_001548) was incubated with
total RNA for 1 h with SuperScript reverse transcriptase
(Gibco-BRL). RNA was digested with RNase A, and ex-
tension products were extracted with phenol–chloro-
form, ethanol precipitated, and resolved by 6% PAGE. The
autoradiographwas obtained by using a Storm Phosphor-
imager system (Molecular Dynamics).
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